Linked Life Data

8256082

Source:http://linkedlifedata.com/resource/pubmed/id/8256082

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1994-1-11
pubmed:abstractText
This is the first randomised double-blind trial of glypressin in the treatment of acute epistaxis, where no localized bleeding point was found and where the patient would normally be treated with a form of nasal packing. It shows a statistically significant benefit with the intravenous drug compared to placebo. In addition, the dose of glypressin used to achieve control appears to be free of major side effects. Acute epistaxis is a common problem, nasal packing is unpleasant and not without side effects, and therefore an alternative form of treatment would have clear advantages. The mechanism of action of glypressin is discussed along with the implications of the results for the future role of glypressin in the treatment of acute epistaxis.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0300-0729
pubmed:author
pubmed:issnType
Print
pubmed:volume
31
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
131-4
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed:year
1993
pubmed:articleTitle
A randomized double-blind trial of glypressin in the management of acute epistaxis.
pubmed:affiliation
Department of ENT Surgery, St. Mary's Hospital, London, United Kingdom.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't